Canine heart base tumors treated with toceranib phosphate
Twenty-eight dogs with histologically, cytologically confirmed or presumed heart based tumors were evaluated. Twenty-seven of the dogs were treated with toceranib alone. An overall response rate of 10% was found and the median survival time was 823 days (range, 68-1190 days). The overall response rate for the dogs presenting with metastasis was 28.5%, with a median survival time of 532 days (range, 77-679 days). This was not significantly different than the median survival time of 796 days for dogs who did not present with metastasis.
Related: Get our Surgical Insights Guide
Of the dogs displaying clinical signs at the time of diagnosis, 90% had improvement and 81% had complete resolution of signs after starting toceranib. Drug toxicity was seen in 54% of dogs with gastrointestinal distress as the most common adverse effect. Results of this study suggests that toceranib phosphate is well-tolerated and effective treatment for inoperable canine heart based tumors including dogs with advanced or metastatic disease.
Read more by clicking on the link below:
